24
Participants
Start Date
December 15, 2017
Primary Completion Date
March 3, 2020
Study Completion Date
June 10, 2020
Axitinib Oral Tablet
"Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities and blood pressure.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day with or without food as per instruction. On clinic days only, patients will be advised to fast for 6 hours prior to their clinic visit.~Patients should be advised to stop axitinib treatment a minimum of 36 hours and maximum of 7 days prior to week 9 nephrectomy and thrombectomy surgery.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
Broomfield Hospital, Chelmsford
Addenbrookes Hospital, Cambridge
Western General Hospital, Edinburgh
Beatson West of Scotland Cancer Centre, Glasgow
Royal Free Hospital, London
St George's Hospital, London
Royal Marsden, London
Collaborators (1)
Pfizer
INDUSTRY
Scottish Clinical Trials Research Unit
OTHER